Last verified 2026-08-16

Zepbound for sleep apnea: what coverage actually looks like

Tirzepatide, sold as Zepbound, is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. It is the only medication with an FDA approval specifically for OSA, which adds a treatment option to a field that for decades centered on machines, appliances, and surgery.

The indication is specific. To fit the approved OSA use, you have to be an adult, meet the obesity criterion, and have moderate-to-severe obstructive sleep apnea confirmed by a sleep study. The approval does not cover mild OSA, central sleep apnea, or OSA in someone who does not meet the weight criterion.

What the trials showed

The approval was supported by two phase 3 trials published in the New England Journal of Medicine. Everyone enrolled had obesity and moderate-to-severe OSA. One trial studied people who were not using PAP. The other studied people already using PAP, with PAP withdrawn before the study measurements were made.

Your sleep study reports a breathing-event rate called the apnea-hypopnea index, or AHI. In the trial involving PAP users, the average AHI fell by about 29 events per hour after a year, compared with about 5 events per hour with placebo. The treatment difference was roughly 24 events per hour.

Across the program, the manufacturer reported average AHI reductions of up to about 63%. Up to about half of participants met the trials’ predefined criteria for disease resolution.

That does not mean everyone who responds can stop other apnea treatment. A reported resolution rate of up to 51.5% also means roughly half of participants did not reach the trial’s resolution threshold. If your AHI starts at 50 and falls by 29 events per hour, you have had a large improvement and can still have moderate sleep apnea.

The trials defined disease resolution using a combination of AHI and sleepiness-scale thresholds. They did not decide it only by asking whether participants felt better. If your weight, symptoms, or medication response changes enough that you are considering stopping PAP or another treatment, repeat measurement is more useful than assuming the apnea is gone.

The trials followed treatment for 52 weeks. Tirzepatide is a weekly injection, and much of its effect on OSA occurs through weight reduction. The trials were not designed to determine what happens to AHI after the medication is stopped. The expected direction is that the sleep apnea will track changes in weight.

The most common adverse effects were gastrointestinal and were generally mild to moderate, consistent with the side-effect pattern seen with this drug class.

Medicare

Medicare Part D can cover Zepbound when it is prescribed for obstructive sleep apnea in a person with obesity. Part D does not cover Zepbound, or another GLP-1 drug, when the only indication is weight loss.

CMS considered broader coverage of anti-obesity medications for 2026 and ultimately did not adopt it. The OSA indication therefore remains a specific route to Part D coverage.

In practice, you need Part D coverage, either through a standalone plan or Medicare Advantage, a documented OSA diagnosis confirmed by a sleep study or home sleep apnea test, and usually prior authorization.

Part D now has an annual out-of-pocket cap for covered drugs, but your cost for Zepbound prescribed for OSA still depends on your Part D plan, formulary status, deductible, and cost-sharing.

The separate Medicare GLP-1 Bridge began in July 2026 and offers a $50 copay for eligible weight-management use. That $50 program does not apply when Zepbound is prescribed for moderate-to-severe OSA. CMS specifically directs beneficiaries using a GLP-1 for a Part D-coverable indication such as OSA to obtain it through their Part D plan instead.

If you were quoted the $50 Bridge price for an OSA prescription, ask your Part D plan what your actual coverage and cost-sharing are.

Commercial insurance

With commercial insurance, your employer’s pharmacy benefit and your plan’s current formulary can matter as much as the diagnosis itself.

Zepbound generally has to be on the formulary, the prior authorization has to be approved, and the initial request has to include the documentation your plan requires. Approvals are often issued for a defined period. Six months is common, after which the plan asks for evidence supporting continued coverage.

Formulary placement can change quickly. In May 2026, CVS Caremark announced that Zepbound would return to its most common commercial formularies as an additional preferred option on October 1, 2026. CVS also notes that employers and other plan sponsors can customize coverage, so a PBM’s standard formulary does not guarantee that your own plan will cover the drug.

Check your plan’s current formulary before the first fill. A prior approval, a PBM announcement, or a coverage decision from an earlier plan year may not describe what your plan covers now.

What prior authorization usually asks for

Published policies vary, but commonly request:

• a prescription for obstructive sleep apnea rather than weight management;
• a diagnosis confirmed by polysomnography or a home sleep apnea test, with the AHI documented;
• documentation that the OSA is moderate-to-severe;
• a body mass index that meets the plan’s threshold; and
• in some plans, documentation about PAP therapy, including whether you tried it, tolerated it, or are using it at the same time.

The PAP requirement differs across plans. Some want you to try PAP first. Some allow Zepbound while PAP continues. Some treat the medication as an add-on rather than a replacement. Your prescriber needs to submit the request in the way your specific policy requires because the same clinical facts can be denied if the request is framed under the wrong indication or missing a required treatment history.

If your request is denied because the drug is being treated only as a weight-loss medication, the FDA indication for OSA is the strongest argument available in the appeal.

Without insurance coverage

List price is roughly $1,000 per month. With coverage, many people pay somewhere between $25 and $150, depending on the plan and formulary tier.

Manufacturer savings programs and direct-purchase options change frequently. Check the manufacturer’s current program directly rather than relying on a fixed number in a third-party article, including this one.

How it fits with other sleep apnea treatment

The trials did not study tirzepatide only as a replacement for PAP. One of the two trials specifically enrolled people who were already using PAP.

You may improve enough that PAP is no longer indicated after repeat testing. You may also have a large reduction in severity and still need PAP or an oral appliance. Both outcomes are consistent with the trial results.

Do not stop existing apnea treatment based only on weight loss, symptom improvement, or a medication response. In the trials, PAP was withdrawn under controlled study conditions and participants were measured again with sleep testing.

If your treatment or weight has changed substantially, a repeat sleep study can show your current AHI and give the clinician managing your care a measured basis for deciding whether the rest of the treatment plan should change.

Coverage rules for this medication are changing quickly. The details above were verified on the date shown and should be checked against your current formulary before you make a coverage decision. This page describes how the drug is approved and covered in the United States. It is not medical advice, and whether the medication is appropriate for you is a decision for the clinician managing your condition.